Price
CHART BY
Frequently asked questions
What is API's market capitalization?
The market capitalization of API is $31.76M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is API's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for API is 2.83. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for API?
API's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.357. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for API's stock?
Currently, 2 analysts cover API's stock, with a consensus target price of $3.50. Analyst ratings provide insights into the stock's expected performance.
What is API's revenue over the trailing twelve months?
Over the trailing twelve months, API reported a revenue of $35.09M.
What is the EBITDA for API?
API's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $10.62M. EBITDA measures the company's overall financial performance.
What is the free cash flow of API?
API has a free cash flow of -$23.25M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does API have, and what sector and industry does it belong to?
API employs approximately 25 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of API's shares?
The free float of API is 31.25M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $31.76M
- EPS (TTM)
- $0.357
- Free Float
- 31.25M
- P/E ratio (TTM)
- 2.83
- Revenue (TTM)
- $35.09M
- EBITDA (TTM)
- $10.62M
- Free Cashflow (TTM)
- -$23.25M
Pricing
- 1D span
- $0.983$1.031
- 52W span
- $0.74$1.78
Analyst Ratings
The price target is $3.50 and the stock is covered by 2 analysts.
Buy
2
Hold
0
Sell
0
Information
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, discovery, and clinical development of targeted radiotherapies. It also develops and markets medicines for relapsed and refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.
- Employees
- 25
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- ATNM
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet